A promising development in cancer research has brought personalised medicine into the spotlight after an experimental mRNA-based vaccine significantly reduced the risk of melanoma returning following surgery.

The treatment, developed jointly by pharmaceutical companies Moderna and Merck, is designed using the genetic characteristics of an individual patient’s tumour. When administered alongside an existing immunotherapy drug, it helped patients remain free from cancer recurrence for longer than those receiving standard immunotherapy alone.

Results from the large Phase 3 INTerpath-001 clinical trial showed that the combination reduced the risk of cancer recurrence or death by 42% compared with treatment using pembrolizumab alone.

The findings offer fresh hope for patients with high-risk melanoma and highlight the growing potential of personalised cancer treatments.

How Does the Personalised Cancer Vaccine Work?

Unlike conventional vaccines designed to prevent infectious diseases, this experimental treatment is intended to help the immune system recognise and attack cancer cells.

The vaccine, known as intismeran autogene, also called V940 or mRNA-4157, uses messenger RNA technology to deliver instructions based on mutations found in a patient’s tumour.

Before the vaccine is produced, doctors analyse genetic material from the removed cancer tissue. Scientists identify specific abnormal proteins, known as neoantigens, that distinguish the tumour cells from healthy cells.

The vaccine is then individually prepared to carry instructions for producing selected tumour-specific targets. It can encode up to 34 neoantigens.

Once administered, the mRNA instructions help the immune system learn to recognise these abnormal targets. The aim is to activate immune cells, particularly T cells, so they can identify and attack cancer cells that may remain in the body after surgery.

Major Phase 3 Trial Involved More Than 1,100 Patients

The international INTerpath-001 trial enrolled 1,137 patients diagnosed with stage IIB to stage IV melanoma that had been completely removed through surgery.

Participants were divided into two groups.

One group received the personalised mRNA vaccine alongside pembrolizumab, an immunotherapy medicine marketed as Keytruda. The other group received pembrolizumab with a placebo.

Researchers followed the participants to determine whether adding the personalised vaccine could prevent the cancer from returning or spreading.

After a median follow-up period of approximately 24.6 months, the combination treatment demonstrated a statistically significant improvement in recurrence-free survival.

The results showed that patients receiving the vaccine combination had a 42% lower risk of cancer recurrence or death compared with those receiving pembrolizumab alone.

More Patients Remained Cancer-Free After Two Years

One of the most encouraging findings involved the proportion of patients who remained alive without their cancer returning.

After two years, approximately 82.2% of patients receiving the personalised vaccine and pembrolizumab remained recurrence-free.

In comparison, the corresponding figure was 70% among patients receiving pembrolizumab alone.

Researchers also reported a 38% reduction in the risk of distant metastasis or death with the combination treatment.

Distant metastasis occurs when cancer spreads from its original location to other parts of the body. Preventing this process is particularly important for people with high-risk melanoma because the disease can become more difficult to treat once it spreads.

Why Is This Research Important?

Melanoma is an aggressive form of skin cancer that develops in pigment-producing cells known as melanocytes.

Although surgery can remove visible tumours, some patients remain at risk because microscopic cancer cells may survive and eventually cause the disease to return.

Immunotherapy medicines such as pembrolizumab help the immune system recognise and attack cancer cells. However, existing treatments do not prevent every recurrence.

The personalised vaccine attempts to strengthen this response by providing the immune system with a more specific set of targets based on the patient’s own tumour.

This approach represents an important shift from treating different patients with identical cancer medicines towards developing treatments that reflect the genetic differences between individual tumours.

What About Side Effects?

The combination treatment was generally manageable, although researchers reported several side effects.

Commonly observed problems included fever, pain around the injection site and fatigue.

More serious adverse events also occurred in some participants, with severe side effects reported somewhat more frequently in the combination group than in the pembrolizumab-only group.

Doctors will need to continue evaluating the treatment’s safety as longer-term clinical data become available.

Is the Cancer Vaccine Available to Everyone?

Despite the encouraging trial results, intismeran autogene remains an investigational treatment and should not be considered an established cure for melanoma.

The findings have demonstrated improvements in recurrence-free survival and distant metastasis-free survival, but overall survival data are not yet mature enough to establish whether the combination helps patients live longer.

Moderna and Merck are engaging with regulatory authorities as they work towards potential approval.

Further follow-up will be necessary to determine how long the benefits last and which patient groups are most likely to respond.

A New Chapter in Personalised Cancer Treatment

The results of the INTerpath-001 trial represent an important milestone in the development of mRNA-based cancer therapies.

The success of this approach could encourage further research into personalised vaccines for other cancers, including lung, kidney and additional tumour types.

Scientists are already investigating whether the same technology can be adapted to recognise the distinctive mutations found in different cancers.

Although significant challenges remain before personalised cancer vaccines become widely available, the latest findings demonstrate how genetic information and immune-based treatments could work together to improve cancer care.

For melanoma patients at high risk of recurrence, the research offers encouraging evidence that a treatment designed around the unique characteristics of their own tumour may provide an additional layer of protection after surgery.